Cytokines profiling by multiplex analysis in experimental arthritis: Which pathophysiological relevance for articular versus systemic mediators?

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Paquet, Joseph ^a   Goebel, Jean Christophe ^a   Delaunay, Camille ^b   Pinzano, Astrid ^a   Grossin, Laurent ^a   Cournil Henrionnet, Christel ^a   Gillet, Pierre ^a   Netter, Patrick ^a   Jouzeau, Jean Yves ^a   Moulin, David ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; RANTES; AUTACOID; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BONE; CARTILAGE; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; JOINT EFFUSION; KNEE ARTHRITIS; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SENSITIZATION; SYNOVIAL FLUID; ANIMAL; ARTHRITIS; ARTICULAR CARTILAGE; BLOOD; COMPARATIVE STUDY; JOINT; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; CYTOKINES; INFLAMMATION MEDIATORS; JOINTS; MALE; RATS; RATS, WISTAR; SYNOVIAL FLUID;

EID: 84857938371     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3774     Document Type: Article

References (73)

1. Gorman CL, Cope AP. Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol 2008, 22:221-238. 10.1016/j.berh.2008.01.003, 18455681.
2. Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, Imhof BA, Koch AE. Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum 2008, 58:3020-3029. 10.1002/art.23867, 2911024, 18821692.
3. Pundt N, Peters MA, Wunrau C, Pap T. Gene therapy in rheumatoid arthritis: new aspects [in German]. Dtsch Med Wochenschr 2008, 133:1737-1741. 10.1055/s-0028-1082797, 18696407.
4. Andreas K, Lubke C, Haupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 2008, 10:R9:1-16. 2374452, 18205922.
5. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. 10.1038/nrd1109, 12776222.
6. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007, 65(Suppl 1):S4-10.
7. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542. 10.1016/j.autrev.2009.01.012, 19189867.
8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916. 10.1056/NEJM200103223441207, 11259725.
9. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007, 104:11742-11747. 10.1073/pnas.0610812104, 1913858, 17609389.
10. Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman D, Jorgensen C, Apparailly F. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 2008, 58:2356-2367. 10.1002/art.23660, 18668557.
11. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 2008, 58:S110-122.
12. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004, 18:59-80. 10.1016/j.berh.2003.09.010, 15123038.
13. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009, 68:1171-1176. 10.1136/ard.2008.091264, 2689520, 18801760.
14. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346. 10.1016/j.semarthrit.2008.10.002, 19117595.
15. Khan IH, Krishnan VV, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom 2009, 76:159-168.
16. Buchner E, Brauer R, Schmidt C, Emmrich F, Kinne RW. Induction of flare-up reactions in rat antigen-induced arthritis. J Autoimmun 1995, 8:61-74.
17. Griffiths RJ. Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Agents Actions 1992, 35:88-95. 10.1007/BF01990957, 1509982.
18. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131. 10.1002/art.21749, 16572447.
19. Pohlers D, Siegling A, Buchner E, Schmidt-Weber CB, Palombo-Kinne E, Emmrich F, Brauer R, Kinne RW. Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther 2005, 7:R445-457. 10.1186/ar1689, 1174936, 15899031.
20. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Kenneth Haines G, Kunkel SL, Burdick MD, Koch AE. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:1266-1277. 10.1002/1529-0131(200006)43:6<1266::AID-ANR9>3.0.CO;2-P, 10857785.
21. Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 2004, 137:65-73. 10.1111/j.1365-2249.2004.02499.x, 1809073, 15196245.
22. Bolon B, Campagnuolo G, Zhu L, Duryea D, Zack D, Feige U. Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee. Vet Pathol 2004, 41:235-243. 10.1354/vp.41-3-235, 15133172.
23. McDougall JJ, Watkins L, Li Z. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain 2006, 123:98-105. 10.1016/j.pain.2006.02.015, 16564620.
24. Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988, 31:956-963. 10.1002/art.1780310803, 2457377.
25. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:584-592.
26. Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, Eberl H, Klause U, Robinson WH. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R102. 10.1186/ar3383, 3218917, 21702928.
27. Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B. Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum 1999, 42:2094-2102. 10.1002/1529-0131(199910)42:10<2094::AID-ANR9>3.0.CO;2-Y, 10524680.
28. Grossin L, Cournil-Henrionnet C, Pinzano A, Gaborit N, Dumas D, Etienne S, Stoltz JF, Terlain B, Netter P, Mir LM, Gillet P. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. Faseb J 2006, 20:65-75. 10.1096/fj.04-2889com, 16394269.
29. Tonussi CR, Ferreira SH. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain 1992, 48:421-427. 10.1016/0304-3959(92)90095-S, 1594266.
30. Tonussi CR, Ferreira SH. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 1999, 82:81-87. 10.1016/S0304-3959(99)00035-4, 10422663.
31. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550. 10.1146/annurev.immunol.021908.132612, 19302047.
32. Pessler F, Mayer CT, Jung SM, Behrens EM, Dai L, Menetski JP, Schumacher HR. Identification of novel monosodium urate crystal regulated mRNAs by transcript profiling of dissected murine air pouch membranes. Arthritis Res Ther 2008, 10:R64. 10.1186/ar2435, 2483455, 18522745.
33. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RL, Crumrine RC, Leenitzer MA, McDougald DL, Han B, Hedeen K, Lin P, Milla M, Moss M, Pink H, Rabinowitz MH, Tippin T, Scates PW, Selph J, Stimpson SA, Warner J, Becherer JD. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 2001, 298:900-908.
34. Fujisawa T, Igeta K, Odake S, Morita Y, Yasuda J, Morikawa T. Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg Med Chem 2002, 10:2569-2581. 10.1016/S0968-0896(02)00109-8, 12057646.
35. Deffaud J, Kirchmeyer M, Domagala F, Ficheux H, Netter P, Bianchi A, Jouzeau JY. Modulatory effect of rhein on IL-1alpha-induced responses in human chondrocytes: a comparative study between antibody microarrays and specific ELISAs. Biorheology 2008, 45:439-455.
36. De Ceuninck F, Dassencourt L, Anract P. The inflammatory side of human chondrocytes unveiled by antibody microarrays. Biochem Biophys Res Commun 2004, 323:960-969. 10.1016/j.bbrc.2004.08.184, 15381094.
37. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
38. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:529-533.
39. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008, 31:175-179. 10.1016/j.jaut.2008.07.002, 18707846.
40. Petrovic-Rackov L. Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid [in Serbian]. Vojnosanit Pregl 2006, 63:21-26. 10.2298/VSP0601021P, 16471244.
41. Leisten JC, Gaarde WA, Scholz W. Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin. Clin Immunol Immunopathol 1990, 56:108-115. 10.1016/0090-1229(90)90174-O, 2113443.
42. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-795. 10.1186/ar1733, 1175027, 15987480.
43. Punzi L, Calo L, Plebani M. Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci 2002, 39:63-88. 10.1080/10408360290795448, 11890208.
44. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 2001, 1:377-385.
45. Krohn KD, Brandt KD, Braunstein E, Mathews V. Hereditary symphalangism. Association with osteoarthritis. J Rheumatol 1989, 16:977-982.
46. Conti P, Reale M, Barbacane RC, Castellani ML, Orso C. Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. Immunol Lett 2002, 80:105-111. 10.1016/S0165-2478(01)00303-0, 11750041.
47. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13:455-481. 10.1016/S1359-6101(02)00045-X, 12401480.
48. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996, 97:604-612. 10.1172/JCI118456, 507095, 8609214.
49. Syversen SW, Goll GL, Haavardsholm EA, Boyesen P, Lea T, Kvien TK. A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthritis Res Ther 2008, 10:R28. 10.1186/ar2381, 2453772, 18312691.
50. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999, 42:1109-1118. 10.1002/1529-0131(199906)42:6<1109::AID-ANR7>3.0.CO;2-7, 10366103.
51. Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, Horuk R, Perez HD. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest 1998, 101:2910-2919. 10.1172/JCI2172, 508883, 9637726.
52. Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, Haas CS, Pope RM, Haines GK, Zha YY, Koch AE. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005, 52:1907-1919. 10.1002/art.21033, 1282452, 15934086.
53. Tetlow LC, Woolley DE. Eosinophils are an insignificant cellular component of rheumatoid synovium in patients with late stage disease: comparative distributions with mast cells and macrophages. Ann Rheum Dis 1996, 55:548-551. 10.1136/ard.55.8.548, 1010236, 8774184.
54. Bockermann R, Holmdahl R. Type II collagen without adjuvant induces eosinophilic arthritis. Eur J Immunol 2007, 37:540-548. 10.1002/eji.200636191, 17236234.
55. Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996, 59:61-66.
56. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Rivo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008, 44:191-200. 10.1016/j.cyto.2008.08.002, 18790652.
57. Boettger MK, Hensellek S, Richter F, Gajda M, Stockigt R, von Banchet GS, Brauer R, Schaible HG. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum 2008, 58:2368-2378. 10.1002/art.23608, 18668541.
58. Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008, 14:245-253. 10.1016/j.molmed.2008.04.001, 18468489.
59. Matsui K, Tsutsui H, Nakanishi K. Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets 2003, 7:701-724. 10.1517/14728222.7.6.701, 14640907.
60. Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N. Expression, purification and structural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol Int 2008, 57:367-376. 10.2332/allergolint.O-08-546, 18797176.
61. Darwich L, Coma G, Pena R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 2008, 126:386-393. 2669819, 18759749.
62. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37. 10.1186/ar1478, 1064899, 15642151.
63. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659. 10.1002/art.20001, 14872510.
64. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008, 58:754-763. 10.1002/art.23222, 18311788.
65. Pacquelet S, Presle N, Boileau C, Dumond H, Netter P, Martel-Pelletier J, Pelletier JP, Terlain B, Jouzeau JY. Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J Rheumatol 2002, 29:2602-2610.
66. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007, 2:251-275. 10.1146/annurev.pathol.2.010506.134925, 18039100.
67. Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol 2006, 2:500-510. 10.1038/ncprheum0291, 16951705.
68. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005, 25:405-428. 10.1615/CritRevImmunol.v25.i5.50, 16167889.
69. Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol 2008, 252:139-145. 10.1016/j.cellimm.2007.09.004, 18289518.
70. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194:809-821. 10.1084/jem.194.6.809, 2195954, 11560996.
71. Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci USA 2008, 105:7240-7245. 10.1073/pnas.0802465105, 2386078, 18480254.
72. Renauld JC. Role of interleukin-9 in asthma and allergic reactions. Bull Mem Acad R Med Belg 2007, 162:275-282.
73. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105:10913-10918. 10.1073/pnas.0801898105, 2491487, 18667700.